After Barclays and BTIG gave Stryker Corporation (NYSE: SYK) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Josh Jennings maintained a Buy rating on Stryker Corporation today and set a price target of $195. The company’s shares closed yesterday at $171.29.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of 3.0% and a 57.9% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and K2M Group Holdings.
Stryker Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $188.57, a 10.1% upside from current levels. In a report issued on October 25, BTIG also maintained a Buy rating on the stock with a $187 price target.
Stryker Corporation’s market cap is currently $64.09B and has a P/E ratio of 52.95. The company has a Price to Book ratio of 6.50.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems.